

## ONCOCYTE TO PARTICIPATE IN 8TH ANNUAL NEEDHAM VIRTUAL MEDTECH & DIAGNOSTICS 1×1 CONFERENCE

Aug 08, 2023

**IRVINE, CA / ACCESSWIRE / August 8, 2023 /** Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15<sup>th</sup>, 2023.

Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative.

## **About Oncocyte**

Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermalO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit <a href="https://oncocyte.com/">https://oncocyte.com/</a>

VitaGraft<sup>™</sup>, DetermalO<sup>™</sup>, and DetermaCNI<sup>™</sup> are trademarks of Oncocyte Corporation.

## **CONTACT:**

Stephanie Prince PCG Advisory (646) 863-6341 <a href="mailto:sprince@pcgadvisory.com">sprince@pcgadvisory.com</a>

**SOURCE**: Oncocyte via PRISM Mediawire. LLC

View source version on accesswire.com:

https://www.accesswire.com/772720/Oncocyte-to-Participate-in-8th-Annual-Needham-Virtual-MedTech-Diagnostics-11-Conference

